Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy

Dirk Dressler, Roongroj Bhidayasiri, Saeed Bohlega, Pedro Chana, Hsin Fen Chien, Tae Mo Chung, Carlo Colosimo, Markus Ebke, Klemens Fedoroff, Bernd Frank, Ryuji Kaji, Petr Kanovsky, Serdar Koçer, Federico Micheli, Olga Orlova, Sebastian Paus, Zvezdan Pirtosek, Maja Relja, Raymond L. Rosales, José Alberto Sagástegui-Rodríguez & 5 others Paul W. Schoenle, Gholam Ali Shahidi, Sofia Timerbaeva, Uwe Walter, Fereshte Adib Saberi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

© 2018, Springer-Verlag GmbH Germany, part of Springer Nature. Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB—Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity—for the first time—based on its various forms of muscle hyperactivity as described in the current movement disorders terminology. We propose the following new definition system: Spasticity describes involuntary muscle hyperactivity in the presence of central paresis. The involuntary muscle hyperactivity can consist of various forms of muscle hyperactivity: spasticity sensu strictu describes involuntary muscle hyperactivity triggered by rapid passive joint movements, rigidity involuntary muscle hyperactivity triggered by slow passive joint movements, dystonia spontaneous involuntary muscle hyperactivity and spasms complex involuntary movements usually triggered by sensory or acoustic stimuli. Spasticity can be described by a documentation system grouped along clinical picture (axis 1), aetiology (axis 2), localisation (axis 3) and additional central nervous system deficits (axis 4). Our new definition allows distinction of spasticity components accessible to BT therapy and those inaccessible. The documentation sheet presented provides essential information for planning of BT therapy.
Original languageEnglish
Pages (from-to)856-862
Number of pages7
JournalJournal of Neurology
DOIs
Publication statusPublished - 1 Apr 2018

Fingerprint

Botulinum Toxins
Movement Disorders
Terminology
Smooth Muscle
Documentation
Joints
Therapeutics
Brain Hypoxia
Muscle Spasticity
Dystonia
Dyskinesias
Spasm
Motor Neurons
Paresis
Acoustics
Brain Neoplasms
Multiple Sclerosis
Germany
Central Nervous System
Stroke

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Dressler, D., Bhidayasiri, R., Bohlega, S., Chana, P., Chien, H. F., Chung, T. M., ... Saberi, F. A. (2018). Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 856-862. https://doi.org/10.1007/s00415-018-8759-1
Dressler, Dirk ; Bhidayasiri, Roongroj ; Bohlega, Saeed ; Chana, Pedro ; Chien, Hsin Fen ; Chung, Tae Mo ; Colosimo, Carlo ; Ebke, Markus ; Fedoroff, Klemens ; Frank, Bernd ; Kaji, Ryuji ; Kanovsky, Petr ; Koçer, Serdar ; Micheli, Federico ; Orlova, Olga ; Paus, Sebastian ; Pirtosek, Zvezdan ; Relja, Maja ; Rosales, Raymond L. ; Sagástegui-Rodríguez, José Alberto ; Schoenle, Paul W. ; Shahidi, Gholam Ali ; Timerbaeva, Sofia ; Walter, Uwe ; Saberi, Fereshte Adib. / Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. In: Journal of Neurology. 2018 ; pp. 856-862.
@article{ebdae2f66e0d4d1b9973a6a842704344,
title = "Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy",
abstract = "{\circledC} 2018, Springer-Verlag GmbH Germany, part of Springer Nature. Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB—Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity—for the first time—based on its various forms of muscle hyperactivity as described in the current movement disorders terminology. We propose the following new definition system: Spasticity describes involuntary muscle hyperactivity in the presence of central paresis. The involuntary muscle hyperactivity can consist of various forms of muscle hyperactivity: spasticity sensu strictu describes involuntary muscle hyperactivity triggered by rapid passive joint movements, rigidity involuntary muscle hyperactivity triggered by slow passive joint movements, dystonia spontaneous involuntary muscle hyperactivity and spasms complex involuntary movements usually triggered by sensory or acoustic stimuli. Spasticity can be described by a documentation system grouped along clinical picture (axis 1), aetiology (axis 2), localisation (axis 3) and additional central nervous system deficits (axis 4). Our new definition allows distinction of spasticity components accessible to BT therapy and those inaccessible. The documentation sheet presented provides essential information for planning of BT therapy.",
author = "Dirk Dressler and Roongroj Bhidayasiri and Saeed Bohlega and Pedro Chana and Chien, {Hsin Fen} and Chung, {Tae Mo} and Carlo Colosimo and Markus Ebke and Klemens Fedoroff and Bernd Frank and Ryuji Kaji and Petr Kanovsky and Serdar Ko{\cc}er and Federico Micheli and Olga Orlova and Sebastian Paus and Zvezdan Pirtosek and Maja Relja and Rosales, {Raymond L.} and Sag{\'a}stegui-Rodr{\'i}guez, {Jos{\'e} Alberto} and Schoenle, {Paul W.} and Shahidi, {Gholam Ali} and Sofia Timerbaeva and Uwe Walter and Saberi, {Fereshte Adib}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s00415-018-8759-1",
language = "English",
pages = "856--862",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",

}

Dressler, D, Bhidayasiri, R, Bohlega, S, Chana, P, Chien, HF, Chung, TM, Colosimo, C, Ebke, M, Fedoroff, K, Frank, B, Kaji, R, Kanovsky, P, Koçer, S, Micheli, F, Orlova, O, Paus, S, Pirtosek, Z, Relja, M, Rosales, RL, Sagástegui-Rodríguez, JA, Schoenle, PW, Shahidi, GA, Timerbaeva, S, Walter, U & Saberi, FA 2018, 'Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy', Journal of Neurology, pp. 856-862. https://doi.org/10.1007/s00415-018-8759-1

Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. / Dressler, Dirk; Bhidayasiri, Roongroj; Bohlega, Saeed; Chana, Pedro; Chien, Hsin Fen; Chung, Tae Mo; Colosimo, Carlo; Ebke, Markus; Fedoroff, Klemens; Frank, Bernd; Kaji, Ryuji; Kanovsky, Petr; Koçer, Serdar; Micheli, Federico; Orlova, Olga; Paus, Sebastian; Pirtosek, Zvezdan; Relja, Maja; Rosales, Raymond L.; Sagástegui-Rodríguez, José Alberto; Schoenle, Paul W.; Shahidi, Gholam Ali; Timerbaeva, Sofia; Walter, Uwe; Saberi, Fereshte Adib.

In: Journal of Neurology, 01.04.2018, p. 856-862.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy

AU - Dressler, Dirk

AU - Bhidayasiri, Roongroj

AU - Bohlega, Saeed

AU - Chana, Pedro

AU - Chien, Hsin Fen

AU - Chung, Tae Mo

AU - Colosimo, Carlo

AU - Ebke, Markus

AU - Fedoroff, Klemens

AU - Frank, Bernd

AU - Kaji, Ryuji

AU - Kanovsky, Petr

AU - Koçer, Serdar

AU - Micheli, Federico

AU - Orlova, Olga

AU - Paus, Sebastian

AU - Pirtosek, Zvezdan

AU - Relja, Maja

AU - Rosales, Raymond L.

AU - Sagástegui-Rodríguez, José Alberto

AU - Schoenle, Paul W.

AU - Shahidi, Gholam Ali

AU - Timerbaeva, Sofia

AU - Walter, Uwe

AU - Saberi, Fereshte Adib

PY - 2018/4/1

Y1 - 2018/4/1

N2 - © 2018, Springer-Verlag GmbH Germany, part of Springer Nature. Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB—Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity—for the first time—based on its various forms of muscle hyperactivity as described in the current movement disorders terminology. We propose the following new definition system: Spasticity describes involuntary muscle hyperactivity in the presence of central paresis. The involuntary muscle hyperactivity can consist of various forms of muscle hyperactivity: spasticity sensu strictu describes involuntary muscle hyperactivity triggered by rapid passive joint movements, rigidity involuntary muscle hyperactivity triggered by slow passive joint movements, dystonia spontaneous involuntary muscle hyperactivity and spasms complex involuntary movements usually triggered by sensory or acoustic stimuli. Spasticity can be described by a documentation system grouped along clinical picture (axis 1), aetiology (axis 2), localisation (axis 3) and additional central nervous system deficits (axis 4). Our new definition allows distinction of spasticity components accessible to BT therapy and those inaccessible. The documentation sheet presented provides essential information for planning of BT therapy.

AB - © 2018, Springer-Verlag GmbH Germany, part of Springer Nature. Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB—Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity—for the first time—based on its various forms of muscle hyperactivity as described in the current movement disorders terminology. We propose the following new definition system: Spasticity describes involuntary muscle hyperactivity in the presence of central paresis. The involuntary muscle hyperactivity can consist of various forms of muscle hyperactivity: spasticity sensu strictu describes involuntary muscle hyperactivity triggered by rapid passive joint movements, rigidity involuntary muscle hyperactivity triggered by slow passive joint movements, dystonia spontaneous involuntary muscle hyperactivity and spasms complex involuntary movements usually triggered by sensory or acoustic stimuli. Spasticity can be described by a documentation system grouped along clinical picture (axis 1), aetiology (axis 2), localisation (axis 3) and additional central nervous system deficits (axis 4). Our new definition allows distinction of spasticity components accessible to BT therapy and those inaccessible. The documentation sheet presented provides essential information for planning of BT therapy.

U2 - 10.1007/s00415-018-8759-1

DO - 10.1007/s00415-018-8759-1

M3 - Article

SP - 856

EP - 862

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -